This Canadian multicenter, open-label randomized controlled trial assessed the efficacy and safety of remdesivir in hospitalized COVID-19 patients. Conducted as part of the WHO Solidarity trial, 1,282 patients were randomized to receive either remdesivir plus standard care or standard care alone. The study found no statistically significant difference in in-hospital
